v3.26.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2023 $ 140,000 $ 319,963,000 $ (256,176,000) $ 63,927,000 $ 19,287,000 $ 83,214,000
Balance, shares at Dec. 31, 2023 7,066,772          
Issuance of common stock, net of expenses $ 20,000 980,000 1,000,000 1,000,000
Issuance of common stock, net of expenses, shares 1,025,746            
Stock based payments 19,000 19,000 19,000
Issuance of common stock, net of expenses - Impact BioMedical, Inc. 1,000 1,890,000 1,891,000 298,000 2,189,000
Net loss (46,896,000) (46,896,000) (6,810,000) (53,706,000)
Balance at Dec. 31, 2024 $ 161,000 322,852,000 (303,072,000) 19,941,000 12,775,000 32,716,000
Balance, shares at Dec. 31, 2024 8,092,518          
Stock based payments 13,000 13,000 13,000
Issuance of common stock, net of expenses - Impact BioMedical, Inc. 1,000 2,082,000 2,083,000 331,000 2,414,000
Net loss (23,929,000) (23,929,000) (3,559,000) (27,488,000)
Issuance of common stock for award $ 20,000 850,000 870,000 870,000
Issuance of common stock for award, shares 1,000,000            
Stock based payments for professional services rendered for Impact Bio 190,000 190,000 190,000
Stock based payments for professional services rendered for Impact Bio, shares            
Balance at Dec. 31, 2025 $ 182,000 $ 325,987,000 $ (327,001,000) $ (832,000) $ 9,547,000 $ 8,715,000
Balance, shares at Dec. 31, 2025 9,092,518